Articles from Virios Therapeutics, Inc. (VIRI)

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets. Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced topline results from its FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 (“HSV-1”)) study of oral IMC-1 for the treatment of FM.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced commencement of enrollment in its exploratory Long-COVID trial. This study is supported via an unrestricted investigational grant to the Bateman Horne Center, a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), FM, post-viral syndromes, and related comorbidities.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it has completed enrollment in its Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 (“HSV-1”)) study, which is a randomized, double-blind evaluation of IMC-1 in patients with fibromyalgia (“FM”).

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today a collaboration with the Bateman Horne Center (“BHC”) of Salt Lake City, Utah, to explore the role of combination antiviral therapy in Long COVID, otherwise known as Post-Acute Sequelae of COVID-19 . The Bateman Horne Center is a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”), fibromyalgia (“FM”), post-viral syndromes, and related comorbidities.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that more than 50% of the patients planned for the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1) study have been randomized.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that its third quarter 2021 financial results will be reported on Thursday, November 11, 2021 before the open of the financial markets. Management will also host a webcast and conference call on November 11, 2021 at 8:30 a.m. ET to discuss the results and provide a corporate update.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference which is taking place virtually September 13 – 15, 2021.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the SNN Network Summer Virtual Conference on August 19, 2021 at 9:00 a.m. ET.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that an interview with Chairman and CEO, Greg Duncan, was aired on Bloomberg TV during The RedChip Money Report®, which delivers commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The interview was focused on the Company’s novel, combination antiviral research programs, with particular emphasis on its ongoing phase 2b fibromyalgia study.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that its second quarter 2021 financial results will be reported on Thursday, August 12, 2021 before the open of the financial markets. Management will also host a webcast and conference call on August 12, 2021 at 8:30 a.m. ET to discuss the results and provide a corporate update.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that all 41 sites involved in its ongoing 460 patient Phase 2b fibromyalgia (FM) trial are now fully activated and enrolling patients. This trial builds on the encouraging results from the Company’s previously completed IMC-1 phase 2a FM clinical study. The 143-patient Phase 2a trial demonstrated that VIRI’s lead antiviral development candidate, orally administered IMC-1, met its primary endpoint of pain reduction and was statistically better tolerated than placebo.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today dosing of the first patient in its Phase 2b clinical trial, referred to as FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1), evaluating IMC-1 in patients with fibromyalgia.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data from its Phase 2a trial of IMC-1 in fibromyalgia (“FM”) is featured in a poster presentation (poster POS0017) at the annual EULAR European Congress of Rheumatology, a renowned forum for interaction between medical doctors, scientists, people with arthritis/rheumatism, health professionals and representatives of the pharmaceutical industry worldwide, which is being held virtually June 2 - 5, 2021. The company’s poster has been selected to be highlighted in a guided tour entitled “Epidemiology and treatment of pain in Rheumatic and Musculoskeletal Disorders.”

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the first quarter ended March 31, 2021.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its first quarter 2021 financial results will be reported on Thursday, May 13, 2021 before the open of the financial markets. Management will also host a webcast and conference call on May 13, 2021 at 8:30 a.m. ET to discuss the results and provide a corporate update.

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today announced an interview with Chairman and CEO, Greg Duncan, will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, April 17, 2021 at 7 p.m. Eastern Time across the United States. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. Eastern Time in 73 million homes.